🇺🇸

US SEC Filing Intelligence

· daily

New Drug Approvals (Original) — August 25, 2026

The August 25, 2026 approval period delivered 4 biosimilar-like fallback approvals with zero NMEs, biosimilars, or label expansions, resulting in a neutral signal across the board. The largest commercial story is the biosimilar approval for NINTEDANIB ESYLATE (BIOCON PHARMA), which directly challenges OFEV (Boehringer Ingelheim), a ~$3B+ franchise in idiopathic pulmonary fibrosis and systemic sclerosis. Other approvals (ASCORBIC ACID, LISINOPRIL, RIVAROXABAN) are for generic/biosimilar versions of widely used, off-patent or near-patent life-cycle drugs, signaling low near-term commercial disruption. The lack of NMEs and heavy concentration of fallback approvals suggests a quiet FDA week with no major pipeline-advancing catalysts for institutional investors.

4 total filings
· daily

US SEC Filings Daily Market Digest — August 25, 2026

Today's filings reveal a market bifurcated between aggressive capital deployment and operational caution. The most significant development is the SPAC merger of Ursa Major with Bleichroeder Acquisition Corp. III, valuing a key defense tech player at $2.3B and signaling strong institutional appetite for next-gen aerospace. In the M&A space, NextEra Energy's $1.38B acquisition of Dominion Energy faces shareholder litigation, while Repligen's merger with BioLife and Navitas Semiconductor's acquisition of Claros highlight consolidation in life sciences and AI infrastructure. Consumer-facing companies like Citi Trends and Marzetti show mixed results, with top-line growth offset by margin pressure. A notable governance scandal at Exyn Technologies (CEO resignation for personal expense misuse) and a Nasdaq compliance extension for Datavault AI underscore elevated micro-cap risk. The financial sector shows steady capital returns, with Equinor's buyback and Ryman Hospitality's $700M debt issuance for a strategic acquisition. Overall, the period-over-period data reveals a 'growth at a cost' theme, with many companies sacrificing near-term profitability for market share or strategic positioning.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 25, 2026

The 12 filings in the S&P 500 Consumer Discretionary stream reveal a mixed but alert picture. The sole substantive operational filing is Home Depot's 10-Q, which shows continued topline growth (+5.7% YoY quarterly revenue) but muted operating profit expansion (+1.1% H1) and a concerning 7% decline in Pro segment comparable sales, signaling a potential softening in the key professional contractor market. This is partially offset by a significant ramp-up in acquisition spending ($1.3B vs $233M YoY). The dominant signal across the stream is a concentrated wave of insider selling at Amazon, with six top executives (including CEO Jassy and CFO Olsavsky) collectively selling over $8.2M in a single day under 10b5-1 plans, which warrants close scrutiny. The four Chipotle filings are unparseable and non-actionable. The portfolio-level trend points to a sector where a major retailer's margins are compressing, while its largest e-commerce and cloud peer's top brass is engaging in a high-volume, coordinated reduction of equity exposure, which could signal a peak-confidence view on the near-term outlook.

12 high priority 12 total filings
· daily

US Earnings Financial Results SEC Filings — August 25, 2026

The 10 filings for this digest reveal a market characterized by stark contrasts: aggressive growth and capital return programs among large-cap retailers are juxtaposed with deteriorating liquidity and rising debt loads at both growth-stage and smaller companies. Home Depot and BJ's Wholesale Club posted strong top-line growth, yet BJ's aggressive share repurchases and store expansion are straining its cash balance. Meanwhile, nCino achieved a significant profitability turnaround (swinging to a $5.1M net income from a $15.3M loss), but its heavy buyback program similarly eroded cash. The biggest divergence is seen in the AI-infrastructure space, where QumulusAI reported a 104% revenue surge driven by compute power, but simultaneously swung to a massive net loss of $72.4M due to debt-related charges, highlighting a classic high-growth/high-burn profile. A consistent theme is aggressive capital allocation: 4 of the 10 companies are conducting significant buybacks, often at the expense of liquidity. Furthermore, operating cash flow pressures are evident, with Electromed and Marzetti showing cash flow declines despite earnings growth. Finally, several micro-cap entities (Mercator, Radiant Strategies, Orion Bliss) remain in pre-revenue or severely distressed positions, offering minimal actionable signals for public equity investors.

10 high priority 10 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 25, 2026

This digest of 8 proxy filings reveals a market bifurcated between distressed SPACs and special-purpose acquisition vehicles racing against liquidation deadlines, and operational companies executing strategic transformations. The most critical development is the high-stakes, time-sensitive nature of several filings: WinVest Acquisition Corp. faces a September 17, 2026 liquidation deadline without an extension, while Hudson Acquisition I Corp. is pursuing a business combination with Aiways Europe after its Nasdaq delisting. Quince Therapeutics' acquisition of Orphai Therapeutics, funded by a $115M private placement, represents a high-risk/high-reward pivot into rare disease, with the company's cash position declining and two reverse stock splits executed. In contrast, Bexil Investment Trust and 374Water are seeking governance changes to increase operational flexibility, while Credo Technology, Cottonwood Communities, and Clark Fork Trust are conducting routine annual meetings. The overarching theme is a 'use it or lose it' environment for SPACs and a 'bet the company' approach for cash-constrained biotechs, with insider and sponsor commitments providing the only safety net for shareholders.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 25, 2026

The IPO pipeline landscape over August 25, 2026, is dominated by a surge in SPAC and de-SPAC activity, alongside traditional biotech and energy technology registrations. Two major proposed mergers (Repligen/BioLife and MiMedx/Sanara) signal intense consolidation in the life sciences tools and wound care sectors, with combined valuations implying significant cost and revenue synergies. AParadise Acquisition Corp. is a non-traditional IPO with restated financials and heavy reliance on related-party financing, raising governance and accounting concerns. Ocean Power Technologies' S-1 is a pure resale registration with zero proceeds for the company, highlighting existing shareholder dilution. Haymaker V's standard SPAC structure with a $250M trust targets an unspecified business combination. Key period-over-period trends are limited as IPOs lack historical comparables, but the MiMedx merger offer ($35.06/share) represents a 15% premium over Sanara's recent trading range, while AParadise's restated financials and net losses signal a high-risk early-stage profile. The most critical pattern is the co-mingling of cash and stock in M&A consideration, creating specific tax and valuation dynamics for arbitrageurs.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — August 25, 2026

The August 25, 2026, trading suspension and delisting intelligence stream reveals a severe cluster of Nasdaq compliance failures across seven small-cap issuers, signaling acute distress in micro-cap and pre-revenue biotech/tech sectors. The dominant theme is a wave of minimum bid price ($1.00) and late-filing violations, with Datavault AI, Fathom Holdings, and Aimei Health Technology all receiving deficiency notices, while Barinthus Biotherapeutics is proactively delisting via a merger. Period-over-period data from La Rosa Holdings shows a 18.0% revenue decline and a 26.0% cash burn, underscoring the financial fragility driving these listing failures. Critically, no insider buying was reported across any of the seven filings, while multiple companies face going-concern risks and negative equity positions, creating a high-risk environment for investors. The most material development is Barinthus's merger-driven delisting, which offers a potential arbitrage opportunity, while the remaining six companies face imminent delisting threats with no clear path to compliance.

7 high priority 7 total filings
· daily

US Executive Officer Management Changes SEC — August 25, 2026

This intelligence stream covering USA Executive & Director Changes reveals a period of significant leadership transition across 37 filings, with a notable concentration of CFO departures and appointments. Key themes include a wave of CFO changes at companies like Renasant Corp, Targa Resources, Sun Communities, Exelon, D-Wave Quantum, and Hope Bancorp, suggesting a broader trend of financial leadership refresh. While most changes are routine succession planning, two high-risk events stand out: the CEO resignation at Exyn Technologies due to personal expense misconduct ($286k) and the SEC-linked board resignation at Netcapital, both carrying material negative sentiment. On the positive side, several appointments bring deep expertise, such as Pure Cycle's new directors with municipal finance and IPO experience, and Parabilis Medicines' addition of a veteran oncology drug developer. Period-over-period comparisons were limited in these governance-focused filings, but Electromed's record FY2026 results (revenue +15.3% YoY, net income +50%) and Eos Energy's $2B in capital secured by its departing CCO provide context for leadership transitions. The overall sentiment is neutral, but the mix of planned retirements, strategic appointments, and a few misconduct-driven exits creates a nuanced landscape for investors to monitor.

37 high priority 37 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 25, 2026

The 37 filings reveal a significant wave of board room changes across diverse sectors, with a notable cluster of CFO transitions and CEO departures. Key themes include strategic succession planning (e.g., REGENXBIO, Exelon, Renasant), governance failures (Exyn Technologies, Netcapital), and restructuring (PDS Biotechnology). Period-over-period comparisons from Electromed show strong financial performance (15.3% revenue growth, 50% net income growth), while negative insider activity and SEC settlements at Netcapital and governance issues at Exyn Technologies are critical red flags. The data suggests a market environment where companies are actively refreshing leadership to navigate growth, regulatory challenges, and operational shifts, creating both risks and opportunities for investors.

37 high priority 37 total filings
· daily

USA Insider Trading Pulse — August 25, 2026

Today's insider trading pulse reveals a bifurcated market with significant insider buying in select value/energy names and notable selling in high-growth technology and consumer sectors. The most material insider purchase was a $20.8M buy by a 10% owner in EBR Systems, signaling strong conviction in the medical device space. Conversely, we observed a pattern of C-suite selling at Sea Ltd (COO sold $1.74M, CCO sold $123K) under 10b5-1 plans, and a notable same-day sell-off by three top executives at Public Policy Holding Company totaling ~$60K, which could indicate coordinated profit-taking or a lack of near-term catalysts. A significant cluster of director stock awards at Leggett & Platt (8 filings) at a depressed stock price of $7.50 suggests the board is being incentivized to drive a turnaround, but the lack of open-market buying is a cautionary signal. The most bearish signal comes from Estee Lauder, where an Exec VP exercised options and immediately sold all resulting shares, netting a $554K profit, a classic sign of bearish sentiment from an insider. Overall, the data suggests a cautious but opportunistic environment, with capital flowing into beaten-down value and special situations while rotating out of names with uncertain growth trajectories.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 25, 2026

The August 25, 2026, US M&A digest reveals a market bifurcated between high-conviction, well-capitalized transactions and struggling SPACs facing existential deadlines. The most significant development is the $2.3B de-SPAC of Ursa Major via Bleichroeder Acquisition Corp. III, a rare high-quality defense-tech target with substantial PIPE backing ($350M+), signaling strong institutional appetite for next-gen aerospace assets. Conversely, a wave of SPAC distress is evident: Hudson Acquisition I Corp. is pursuing a $410M EV deal with Aiways Europe while already delisted from Nasdaq, and Quartzsea and BEST SPAC face Nasdaq non-compliance. The period is marked by capital recycling, as Steele Creek Capital liquidates 75.8% of its loan portfolio and Two Harbors Investment Corp. completes its $12/share take-private by CrossCountry Mortgage. A notable trend is the use of contingent consideration and stock in smaller M&A, as seen in reAlpha Tech Corp.'s $8.5M acquisition of InstaMortgage, which closed without key regulatory approvals, creating material operational risk. Overall, the data shows a market where capital is flowing to premium assets (defense, aircraft leasing) while structurally challenged SPACs and small-cap acquirers face mounting pressure.

16 high priority 16 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 25, 2026

The overnight filing set is dominated by M&A and insider activity, with the most critical development being NextEra Energy's voluntary supplemental disclosures for its $9B+ acquisition of Dominion Energy, which faces shareholder lawsuits threatening a September 3 vote. A second major M&A signal comes from Navitas Semiconductor's agreement to acquire Claros for up to $232.8 million, doubling its addressable market to $8B+ and positioning it in AI data center power management — a high-growth thematic. Insider activity is mixed but notable: the CEO of Prenetics Global bought ~$239K in stock at ~$21.40, a strong bullish signal for a micro-cap, while Procore Technologies saw multiple C-suite tax-withholding sales totaling ~$4.9M at ~$63, which is typical but heavy in volume. On the negative side, the CEO of Fold Holdings sold stock at ~$0.48-0.49, and Namib Minerals’ beneficial owner disclosed a dilutive share loan of up to 14M shares carrying 13% interest, creating overhang. Teekay Tankers awarded dividend equivalent rights, signaling a steady return of capital. XPeng and Vipshop both filed unremarkable 6-Ks. Period-over-period trends are sparse, but Molecular Partners showed a 28% YoY improvement in net loss to CHF -26.7M, a positive turn in cash burn. The overall tone is neutral-to-bullish on M&A and selected insider buys, with material risk from litigation and dilution in a few names.

42 high priority 8 medium 50 total filings
· daily

New Federal Contractors — August 24, 2026

This digest covers a single, large civilian contract awarded to Amentum Technology, Inc. by NASA Ames Research Center, valued at $239.3 million in total obligations out of a $293 million ceiling. The contract is for aerospace testing and facilities operations at Moffett Field, CA, under a cost-plus-fixed-fee structure, and its performance period ended in August 2022. With zero defense-related awards and a neutral signal strength of 5/10, the investment story is muted: the contract represents stable, low-risk revenue for Amentum but is largely historical, offering limited forward-looking insight. The key risk is the absence of a recompete or follow-on contract, which could create a revenue gap for Amentum’s facilities support segment.

1 total filings
· daily

Significant Contract Modifications ($10M+) — August 24, 2026

The two NASA contracts analyzed, totaling $239.7 million, are exclusively civilian in nature, with zero defense exposure. The dominant theme is stable, low-risk operational support for NASA’s aerospace testing infrastructure, led by Amentum Technology’s $239.3 million cost-plus-fixed-fee contract at Ames Research Center. However, the highest-conviction signal is a bearish one: the Amentum contract’s performance period ended in August 2022, meaning it is likely completed or near completion, removing a significant revenue stream from the company’s forward-looking backlog. The sole-source $424,164 Lockheed Martin award is immaterial to that company’s $60B+ revenue base. The key risk is the absence of any recompete or follow-on contract data for the Amentum award, creating a potential revenue gap for the contractor in NASA facilities support.

2 total filings
· daily

Contract Deobligations Alert — August 24, 2026

The combined $239.7M in contract activity is overwhelmingly civilian (NASA-only, 100% non-defense), with Amentum Technology's $239.3M NASA Ames facilities support contract dominating 99.8% of total obligation. The second contract—a $424K sole-source R&D award to Lockheed Martin—is immaterial to that company's revenue but signals entrenched positioning in NASA's space R&D ecosystem. The average signal strength of 3.5/10 reflects that the largest contract (by value) is aged and nearly complete, limiting forward-looking investment relevance. Key risk: Amentum's NASA revenue stream is effectively sunsetting with no visible re-compete trigger, exposing a potential backlog gap. No bullish or bearish signals were identified across the two awards.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 24, 2026

The August 24, 2026 batch of 26 filings from the S&P 500 Technology sector is dominated by routine insider equity exercises and tax-withholding transactions at Arista Networks, Salesforce, and a few other names, with no material period-over-period comparisons, forward-looking guidance, or capital allocation changes reported. The most notable event is a concentrated wave of insider stock exercises and tax-withholding sales at Arista Networks, where the President & COO alone had 63,540 shares withheld for taxes (~$11.8M) and the CEO had 13,855 shares withheld (~$2.58M), signaling large equity compensation vesting but no outright open-market selling. A single negative signal comes from Palantir Technologies, where a 'See Remarks' insider sold shares under a 10b5-1 plan at ~$174.85, though the dollar amount is modest. Overall, the filings suggest a quiet period with no major strategic pivots, guidance updates, or capital allocation changes; the primary takeaway is the magnitude of equity compensation vesting at Arista, which investors should monitor for potential future selling pressure.

24 high priority 2 medium 26 total filings
· daily

Nasdaq 100 Stocks SEC Filings — August 24, 2026

The four filings from the NASDAQ-100 stream reveal a stark contrast between a major capital markets maneuver by Strategy Inc and routine insider trading activity at NVIDIA and Palantir. The most significant development is Strategy Inc's establishment of a new $1.59 billion liquidity pool ('USD Cash') and its aggressive equity issuance of $2.01 billion via MSTR share sales, while simultaneously executing a $136.4 million buyback of its STRC shares. This capital allocation strategy, coupled with zero bitcoin purchases for the week, signals a potential shift from aggressive accumulation to balance sheet optimization and shareholder returns. Meanwhile, insider selling at Palantir by a director under a 10b5-1 plan, while not alarming, provides a subtle negative signal against the backdrop of the company's elevated valuation. The NVIDIA filing is a routine beneficial ownership report with no actionable market signal. The key portfolio-level pattern is the divergence in capital deployment: one company is aggressively raising and reallocating capital, while others show no significant corporate actions.

1 high priority 3 medium 4 total filings